Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

Hua Medicine Begins Phase I Trial of Novel Diabetes Treatment

publication date: Sep 6, 2013
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Hua Medicine has begun a China Phase I clinical trial of a novel Glucokinase activator treatment for diabetes 2. The CFDA gave HMS5552, as the Hua drug is known, the designation of type 1.1 novel drug because no drug of the Glucokinase activator class has been approved anywhere in the world. Hua in-licensed China rights to the drug from Roche two years ago. In a statement, Dr. Li Chen, CEO of Hua Medicine, noted that it was a significant milestone for Hua to start clinical development in China of an innovative diabetes treatment that is intended for the world’s market. More details....

Stock Symbol: (SX: ROG)

Share this with colleagues:  


This article is available for purchase - please click here for details.


Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Partner Events

Bio Taiwan 2015
July 22-26, 2015
Taipei, Taiwan


BioPharm America™ 2015
September 15–17, 2015
Boston, USA

>> More events...
Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Sponsors